Oxular

One treatment a year. Life changing. Oxular is developing disruptive treatments for retinal diseases. Oxulars sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxulars drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxulars product development pipeline includes treatments...

Ophthalmology,biotechnology,ocular,dme,diabetic macular edema,retinoblastoma,microreservoirs,oxulumis,oxuflo,amd,age-related macular degeneration,retinal disease,therapeutics,treatment,anti-vegf,gene therapy,uveitis,uveal melanoma,and retinal inflammation

Oxular operates in the Biotechnology industry.

Oxular's revenue is 1m - 10m

Oxular has 11 - 50 employees.